Torrent Pharmaceuticals has been assigned an Environmental, Social, and Governance (ESG) rating of 70 by NSE Sustainability Ratings and Analytics Limited. The rating agency, which is registered with the Securities and Exchange Board of India (SEBI), conducted an independent assessment of the pharmaceutical company’s sustainability practices. This disclosure provides investors with a standardized metric to evaluate the firm’s non-financial performance risks and opportunities.

The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) regarding the rating assignment on August 11, 2026. The intimation was issued pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the disclosure aligns with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026, which mandates transparency in ESG rating disclosures for listed entities.

Rating Details

The specific details of the ESG assessment are outlined below:

Chintan M. Trivedi, Company Secretary at Torrent Pharmaceuticals, signed the regulatory filing. The notification confirms that the rating was derived through an independent evaluation process, ensuring objectivity in the assessment of the company’s environmental impact, social responsibility, and governance structures.

What the Numbers Show

An ESG score of 70 places Torrent Pharmaceuticals within a specific band of sustainability performance as defined by NSE Sustainability Ratings and Analytics Limited. While the source document does not provide a comparative benchmark against industry peers or prior periods, the assignment of a numeric score allows for longitudinal tracking of the company’s ESG trajectory. Investors typically use such ratings to screen for companies with robust governance frameworks and lower operational risks related to environmental or social controversies. The reliance on a SEBI-registered provider adds a layer of regulatory credibility to the score, distinguishing it from voluntary or unregulated sustainability claims.

Torrent Pharmaceuticals Limited has completed the electronic dispatch of its postal ballot notice to shareholders seeking approval for the appointment of Shanti Ekambaram as an Independent Director. The company confirmed on August 6, 2026, that the notice was sent via email to members registered as of the July 31, 2026 cut-off date, in compliance with Ministry of Corporate Affairs (MCA) circulars and SEBI Listing Regulations. This procedural step activates the voting window for the special resolution, which aims to bring Ms. Ekambaram’s extensive financial services expertise to the Board to strengthen governance frameworks.

The voting process is governed by Section 110 of the Companies Act, 2013, Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In adherence to MCA General Circulars No. 14/2020, 17/2020, and 03/2025, physical copies of the ballot were not distributed; instead, Central Depository Services (India) Limited (CDSL) facilitates e-voting. The Company Secretary, Chintan M. Trivedi, signed the intimation filed with stock exchanges on August 6, confirming the dispatch was completed on August 5, 2026.

Ms. Ekambaram, aged 63, brings 39 years of experience in financial services, including a 35-year tenure at Kotak Mahindra Bank where she served as Deputy Managing Director until 2025. She previously led Kotak Mahindra Capital Company and holds directorships at Havells India Limited, Kotak Securities Limited, and Kotak Mahindra Capital Company Limited. Her appointment is proposed for a term of three consecutive years, effective from July 30, 2026, subject to shareholder assent. She is not liable to retire by rotation under Section 149(13) read with the explanation to Section 152(6) of the Companies Act, 2013.

Key Voting Details

Members holding shares in physical or demat form as of the cut-off date are eligible to vote. Individual demat holders can access the e-voting facility via their depository login credentials on the CDSL platform. Non-individual members and those holding physical shares must register on the CDSL e-voting portal using their folio or beneficiary details. Technical support for CDSL and NSDL logins is available through dedicated helpdesk channels provided in the notice.

Board Composition and Remuneration

Upon confirmation by shareholders, Ms. Ekambaram will serve as a member of the Audit Committee, Securities Transfer and Stakeholders Relationship Committee, and the Nomination and Remuneration Committee. She does not hold any shares in Torrent Pharmaceuticals Limited and has no relationship with other directors or key managerial personnel. Since her interim appointment as an Additional Director on July 30, 2026, she has attended one board meeting and received remuneration of ₹ 1 lakh in the form of sitting fees. Her future remuneration will be determined in accordance with Resolution No. 9 of the 51st Annual General Meeting Notice dated May 24, 2024, or subsequent resolutions passed by members. Rajesh Parekh & Co. has been appointed as the scrutinizer, with Aishwarya Parekh of RPAP & Co. serving as the alternate scrutinizer to ensure the fairness and transparency of the voting process.